GSK alli agreement

Executive Summary

GlaxoSmithKline announces Feb. 20 it has acquired from Roche exclusive rights to weight-loss drug orlistat (alli) for OTC use in markets outside the U.S. excluding Japan. Roche retains marketing rights for the orlistat product Xenical for Rx use. GSK says in a release it anticipates filing orlistat for OTC approval in Europe and other key international markets by the end of 2007. FDA approved alli for OTC use Feb. 7 and GSK plans to launch alli by this summer (1"The Tan Sheet," Feb. 12, 2007, p. 8)...